SCHEMBL4973274

SCHEMBL4973274

CCC1(CO)COC(C)(CC)OC1

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.41
KDM4E B2RXH2 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10585520 0.93 EPHX1 (0.42) EPHX1
SCHEMBL1108447 0.84 EPHX1 (0.42) EPHX1KDM4EGAA
SCHEMBL9619323 0.84 EPHX1 (0.54) EPHX1
SCHEMBL9619380 0.82 EPHX1 (0.34) EPHX1
Methane SCHEMBL9788186 0.82 EPHX1 (0.41) EPHX1KDM4EGAA
SCHEMBL3047193 0.82 EPHX1 (0.32) EPHX1
SCHEMBL5161498 0.81 EPHX1 (0.39) EPHX1KDM4EGAA
SCHEMBL4815468 0.79 EPHX1 (0.37) EPHX1KDM4EGAA
SCHEMBL21283654 0.77 EPHX1 (0.36) EPHX1KDM4EGAA
SCHEMBL9619426 0.77 EPHX1 (0.37) EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735010-A4 METHODS, COMPOSITIONS, AND PREPARATIONS FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES CO (US) 2008-08-27 EP disclosed
US-20070166384-A1 Methods , composition and preparations for delivery of immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY 2007-07-19 US disclosed
US-20070166384-A1 Methods , composition and preparations for delivery of immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY 2007-07-19 US disclosed
US-20070166384-A1 Methods , composition and preparations for delivery of immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY 2007-07-19 US disclosed
EP-1646673-B1 (METH)ACRYLIC ACID ESTERS OF MONOALKOXYLATED POLYOLS, AND PRODUCTION THEREOF BASF AG (DE) 2007-03-14 EP disclosed
EP-1735010-A2 METHODS, COMPOSITIONS, AND PREPARATIONS FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS 3M Innovative Properties Company (US) 2006-12-27 EP disclosed
EP-1646673-A1 (METH)ACRYLIC ACID ESTERS OF MONOALKOXYLATED POLYOLS, AND PRODUCTION THEREOF BASF AKTIENGESELLSCHAFT (DE) 2006-04-19 EP disclosed
WO-2005110013-A2 METHODS, COMPOSITIONS, AND PREPARATIONS FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-24 WO disclosed
WO-2005005514-A1 (METH)ACRYLIC ACID ESTERS OF MONOALKOXYLATED POLYOLS, AND PRODUCTION THEREOF BASF AKTIENGESELLSCHAFT (DE) 2005-01-20 WO disclosed
EP-1034204-B1 ROOM TEMPERATURE CURABLE SILANE TERMINATED AND STABLE WATERBORNE POLYURETHANE DISPERSIONS WHICH CONTAIN FLUORINE AND/OR SILICONE AND LOW SURFACE ENERGY COATINGS PREPARED THEREFROM MINNESOTA MINING & MFG (US) 2004-02-11 EP disclosed
US-6313335-B1 Room temperature curable silane terminated and stable waterborne polyurethane dispersions which contain fluorine and/or silicone and low surface energy coatings prepared therefrom 3M INNOVATIVE PROPERTIES 2001-11-06 US disclosed
EP-1034204-A1 ROOM TEMPERATURE CURABLE SILANE TERMINATED AND STABLE WATERBORNE POLYURETHANE DISPERSIONS WHICH CONTAIN FLUORINE AND/OR SILICONE AND LOW SURFACE ENERGY COATINGS PREPARED THEREFROM MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2000-09-13 EP disclosed
WO-1999026992-A1 ROOM TEMPERATURE CURABLE SILANE TERMINATED AND STABLE WATERBORNE POLYURETHANE DISPERSIONS WHICH CONTAIN FLUORINE AND/OR SILICONE AND LOW SURFACE ENERGY COATINGS PREPARED THEREFROM MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-06-03 WO disclosed
EP-0247472-B1 PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID DERIVATIVES BAYER AG (DE) 1992-02-12 EP disclosed
EP-0247472-A2 Process for the preparation of carboxylic acid derivatives BAYER AG (DE) 1987-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070166384-A1 Methods , composition and preparations for delivery of immune response modifiers TLR3, MYD88, IFNG EPHX1 2649/4885KDM4E 3888/4885GAA 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.